Peter Salzmann compensation by year
Immunovant Summary Compensation Table · all 7 fiscal years held| Component | FY2019 | FY2020 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|
| Salary | $361,010 | $567,000 | $600,000 | $625,000 | $700,000 | $724,500 | $39,614 |
| Bonus | $500,000 | $311,850 | $346,500 | $360,938 | $609,000 | $470,925 | $0 |
| Stock awards | $0 | $3,252,500 | $3,999,997 | $2,251,807 | $3,584,330 | $4,941,237 | $8,287,949 |
| Option awards | $7,721,344 | $11,104,950 | $888,389 | $2,544,313 | $3,619,675 | $4,539,890 | $6,269,395 |
| Non-equity incentive | $224,480 | $0 | $0 | $0 | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $0 | $139,004 | $33,455 | $37,760 | $39,425 | $55,575 | $737,642 |
| Total | $8,806,834 | $15,375,304 | $5,868,341 | $5,819,818 | $8,552,430 | $10,732,127 | $15,334,600 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Immunovant, Inc. DEF 14A filed July 22, 2026, accession 0001764013-26-000092, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Immunovant, Inc. filed document, accession 0001764013-26-000092. Every figure is read from that document and cited to the page and table it appears in. Filed July 22, 2026.
Equity holdings
unvested awards at FY2026 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 265,820 | $6,602,969 | — |
| RSU | 90,301 | $2,243,077 | — |
| RSU | 76,198 | $1,892,758 | — |
| RSU | 56,408 | $1,401,175 | — |
| Option | 374,395 | — | $15.20 |
| Option | 85,742 | — | $14.70 |
| Option | 70,687 | — | $4.99 |
| Option | 104,515 | — | $30.78 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Immunovant, Inc.'s FY2026 proxy; value at the fiscal year-end close, as the company printed it.
Immunovant’s named executive officers, FY2026
as the company reported each| Named executive officer | Role | FY2026 total |
|---|---|---|
| Eric Venker | Chief Executive Officer | $20,158,767 |
| Peter Salzmann · this page | Former Chief Executive Officer | $15,334,600 |
| Tiago Girão | Chief Financial Officer | $7,616,437 |
| Michael Geffner | Former Chief Medical Officer | $5,254,089 |
| Eva Renee Barnett | Former Chief Financial Officer | $3,227,452 |
| Melanie Gloria | Chief Operating Officer | $3,067,112 |
| Jay Stout | Chief Technology Officer | $3,065,721 |
| Christopher Van Tuyl | Chief Legal Officer and Corporate Secretary | $2,295,777 |
Board service
Immunovant board · FY2021–FY2026How this board is paid
Company policy: Immunovant pays directors a $50,000 cash retainer and $425,000 in 75% RSU / 25% Option. As stated in Immunovant's FY2026 proxy.
The full Immunovant compensation record
free company briefThis page is one person within Immunovant's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Immunovant proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Immunovant's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Immunovant's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order IMVT
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.